S&P 500
5.214,08 +26,41 (+0,51%) Nasdaq
16.346,26 +43,46 (+0,27%) NIKKEI 225
38.297,21 +223,23 (+0,59%) Dólar/Euro
1,0778 -0,0006 (-0,05%) Petróleo Brent
84,23 +0,35 (+0,42%) Bitcoin EUR
58.376,43 +1.246,36 (+2,18%)
IGC Pharma, Inc. (IGC)
Después del cierre:
IGC Pharma, Inc.
10224 Falls Road
Potomac, MD 20854
United States
301 983 0998
https://igcpharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 61
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Ram Mukunda | President, CEO & Director | 705k | N/A | 1959 |
| Ms. Claudia Grimaldi | VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director | 245k | N/A | 1971 |
| Mr. Rohit Goel | Senior Director of Accounting & Principal Accounting Officer | N/A | N/A | 1994 |
Descripción
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
Gobierno corporativo
El ISS Governance QualityScore de IGC Pharma, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
